OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free ENZN Stock Alerts $0.08 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.07▼$0.0850-Day Range$0.06▼$0.0952-Week Range$0.06▼$0.22Volume900 shsAverage Volume6,246 shsMarket CapitalizationN/AP/E Ratio8.35Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Enzon Pharmaceuticals alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Read More ENZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENZN Stock News HeadlinesNovember 8, 2023 | morningstar.comEnzon Pharmaceuticals Inc ENZNOctober 25, 2023 | finance.yahoo.comOKYO Pharma Limited (OK10.F)April 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.July 30, 2023 | nasdaq.comRegeneron Pharmaceuticals, Inc. Common Stock (REGN)March 26, 2023 | thestreet.comEnzon Stock Hits New 52-Week Low (ENZN)March 20, 2023 | investing.comIbnsina Pharma Co (ISPH)February 26, 2023 | time.comBig Pharma’s Patent Abuses Are Fueling the Drug Pricing CrisisJuly 15, 2022 | morningstar.comEnzon Pharmaceuticals Inc - Stock Operating Performance ENZNApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.July 2, 2022 | finance.yahoo.comEnzon Pharmaceuticals, Inc. (ENZN)See More Headlines Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CUSIP29390410 CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio8.35 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.37 million Net MarginsN/A Pretax Margin3,573.08% Return on Equity46.47% Return on Assets2.92% Debt Debt-to-Equity RatioN/A Current Ratio27.62 Quick Ratio27.62 Sales & Book Value Annual Sales$30,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.33 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Richard L. Feinstein (Age 81)CEO, CFO & Company Secretary Comp: $209.45kKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAlvotechNYSE:ALVOAVAX TechnologiesOTCMKTS:AVXTGenocea BiosciencesNASDAQ:GNCAQMymeticsOTCMKTS:MYMXView All Competitors ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed in 2024? Enzon Pharmaceuticals' stock was trading at $0.0936 at the start of the year. Since then, ENZN stock has decreased by 10.8% and is now trading at $0.0835. View the best growth stocks for 2024 here. Are investors shorting Enzon Pharmaceuticals? Enzon Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 12,900 shares, an increase of 239.5% from the March 31st total of 3,800 shares. Based on an average trading volume of 21,800 shares, the days-to-cover ratio is currently 0.6 days. View Enzon Pharmaceuticals' Short Interest. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) posted its quarterly earnings results on Wednesday, March, 20th. The biotechnology company reported $0.01 earnings per share for the quarter. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Golar LNG Partners (GMLP), Washington Prime Group (WPG), DHT (DHT), Hallador Energy (HNRG) and Medical Marijuana (MJNA). How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ENZN) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.